Literature DB >> 16467563

Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis.

Stephen M Eggan1, David A Lewis.   

Abstract

Delta-9-tetrahydrocannabinol (Delta9-THC) has profound effects on higher cognitive functions, and exposure to Delta9-THC has been associated with the appearance or exacerbation of the clinical features of schizophrenia. These actions appear to be mediated via the CB1 receptor, the principal cannabinoid receptor expressed in the brain. However, the distribution of the CB1 receptor in neocortical regions of the primate brain that mediate cognitive functions is not known. We therefore investigated the immunocytochemical localization of the CB1 receptor in the brains of macaque monkeys and humans using antibodies that specifically recognize the N- or C-terminus of the CB1 receptor. In monkeys, intense CB1 immunoreactivity was observed primarily in axons and boutons. Across neocortical regions of the monkey brain, CB1-immunoreactive (IR) axons exhibited considerable heterogeneity in density and laminar distribution. Neocortical association regions, such as the prefrontal and cingulate cortices, demonstrated a higher density, and exhibited a unique laminar pattern of CB1-IR axons, compared with primary sensory and motor cortices. Similar regional and laminar distributions of CB1-IR axons were also present in the human neocortex. CB1-IR axons had more prominent varicosities in human tissue, but this difference appeared to represent a postmortem effect as similar morphological features increased in unperfused monkey tissue as a function of postmortem interval. In electron microscopy studies of perfused monkey prefrontal cortex, CB1 immunoreactivity was predominantly found in axon terminals that exclusively formed symmetric synapses. The high density, distinctive laminar distribution, and localization to inhibitory terminals of CB1 receptors in primate higher-order association regions suggests that the CB1 receptor may play a critical role in the circuitry that subserves cognitive functions such as those that are disturbed in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467563     DOI: 10.1093/cercor/bhj136

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  114 in total

1.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

2.  Functional connectivity in brain networks underlying cognitive control in chronic cannabis users.

Authors:  Ian H Harding; Nadia Solowij; Ben J Harrison; Michael Takagi; Valentina Lorenzetti; Dan I Lubman; Marc L Seal; Christos Pantelis; Murat Yücel
Journal:  Neuropsychopharmacology       Date:  2012-04-25       Impact factor: 7.853

3.  The effect of chronic cannabinoids on broadband EEG neural oscillations in humans.

Authors:  Patrick D Skosnik; Deepak C D'Souza; Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

4.  Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study.

Authors:  Michael Kiang; Bruce K Christensen; David L Streiner; Carolyn Roy; Iulia Patriciu; Robert B Zipursky
Journal:  Psychopharmacology (Berl)       Date:  2012-07-11       Impact factor: 4.530

5.  Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia.

Authors:  Monica Beneyto; Andrew Abbott; Takanori Hashimoto; David A Lewis
Journal:  Cereb Cortex       Date:  2010-09-15       Impact factor: 5.357

6.  Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution.

Authors:  Robert A Battisti; Steven Roodenrys; Stuart J Johnstone; Nicole Pesa; Daniel F Hermens; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2010-08-19       Impact factor: 4.530

Review 7.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 8.  What is the mechanism whereby cannabis use increases risk of psychosis?

Authors:  Sonija Luzi; Paul D Morrison; John Powell; Marta di Forti; Robin M Murray
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

10.  Emotion regulation deficits in regular marijuana users.

Authors:  Kaeli Zimmermann; Christina Walz; Raissa T Derckx; Keith M Kendrick; Bernd Weber; Bruce Dore; Kevin N Ochsner; René Hurlemann; Benjamin Becker
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.